Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Ferdynand J KosPaul H FrankelMihaela C CristeaMelissa EngRaechelle TinsleyShannon DempseyNora RuelDaphne StewartThanh H DellingerDon J DiamondPublished in: Cancer research communications (2023)
p53MVA/pembrolizumab immunotherapy showed promising anti-tumor activity in patients who demonstrated functionally competent peripheral blood T cells. Detection of markers of terminally differentiated T cells before treatment may identify patients unlikely to respond to p53MVA/pembrolizumab.